Quantbot Technologies LP Has $581,000 Holdings in LivaNova PLC (NASDAQ:LIVN)

Quantbot Technologies LP trimmed its position in shares of LivaNova PLC (NASDAQ:LIVN) by 66.8% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 12,546 shares of the company’s stock after selling 25,215 shares during the quarter. Quantbot Technologies LP’s holdings in LivaNova were worth $581,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also made changes to their positions in the company. Central Pacific Bank Trust Division lifted its stake in LivaNova by 21.2% in the fourth quarter. Central Pacific Bank Trust Division now owns 4,117 shares of the company’s stock valued at $191,000 after acquiring an additional 720 shares during the last quarter. Captrust Financial Advisors acquired a new stake in shares of LivaNova in the 3rd quarter valued at $217,000. Sanctuary Advisors LLC acquired a new stake in shares of LivaNova in the 3rd quarter valued at $219,000. Vestcor Inc bought a new stake in LivaNova in the fourth quarter worth $204,000. Finally, Edgestream Partners L.P. acquired a new position in LivaNova during the third quarter worth $244,000. Institutional investors own 97.64% of the company’s stock.

LivaNova Price Performance

NASDAQ:LIVN opened at $39.62 on Friday. The company has a debt-to-equity ratio of 0.46, a current ratio of 3.37 and a quick ratio of 2.87. The stock has a market cap of $2.15 billion, a P/E ratio of 94.33 and a beta of 1.10. The company has a fifty day moving average price of $44.69 and a 200 day moving average price of $48.52. LivaNova PLC has a one year low of $36.85 and a one year high of $64.48.

Analyst Ratings Changes

Several analysts have recently issued reports on LIVN shares. The Goldman Sachs Group decreased their price target on LivaNova from $64.00 to $55.00 and set a “buy” rating for the company in a research note on Monday, March 3rd. Needham & Company LLC reaffirmed a “buy” rating and set a $64.00 target price on shares of LivaNova in a research report on Monday, March 17th. Wolfe Research downgraded LivaNova from an “outperform” rating to a “peer perform” rating in a report on Wednesday, February 26th. Stifel Nicolaus reduced their price objective on shares of LivaNova from $72.00 to $60.00 and set a “buy” rating for the company in a research note on Wednesday, February 26th. Finally, Mizuho lowered their target price on shares of LivaNova from $70.00 to $60.00 and set an “outperform” rating on the stock in a research note on Wednesday, February 26th. Two equities research analysts have rated the stock with a hold rating, five have issued a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $61.17.

LivaNova Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.